Technical Perspectives on Biotech Stocks -- AnaptysBio, Anthera Pharma, Aralez Pharma, and Aratana Therapeutics

Friday, February 23, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Feb. 23, 2018 /PRNewswire/ -- strives to bring the best free research to the investment

community.  Today we are offering reports on ANAB, ANTH, ARLZ, and PETX which can be accessed for free by signing up to Pre-market today, scans AnaptysBio Inc. (NASDAQ: ANAB), Anthera Pharmaceuticals
Inc. (NASDAQ: ANTH), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Aratana Therapeutics Inc. (NASDAQ: PETX). Biotechnology companies are engaged in the research and development of biological substances, primarily for the purpose of drug discovery and diagnostic development. All you have to do is sign up today for this free limited time offer by clicking the link below.


Shares in San Diego, California-based AnaptysBio Inc. saw a decline of 1.34%, ending Thursday's trading session at $119.43. The stock recorded a trading volume of 124,344 shares. The Company's shares have gained 4.04% in the last month, 58.69% over the last three months, and 415.90% over the past year. The stock is trading 13.68% and 114.10% above its 50-day and 200-day moving averages, respectively. Moreover, shares of AnaptysBio, which engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the US, have a Relative Strength Index (RSI) of 58.51.  

On February 15th, 2018, research firm SunTrust reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $115 a share to $162 a share.

On February 17th, 2018, AnaptysBio announced that updated data from its Phase-2a trial of ANB020, the Company's wholly owned anti-IL-33 antibody program, in adult patients with moderate-to-severe atopic dermatitis was presented that day at the American Academy of Dermatology Annual Meeting in San Diego. The oral presentation, titled "Proof-of-Concept Phase-2a Clinical Trial of ANB020 (Anti-IL-33 Antibody) in the Treatment of Moderate-to-Severe Adult Atopic Dermatitis," was presented by the principal investigator of the ANB020 Phase-2a clinical trial, Dr. Graham Ogg. Get the full research report on ANAB for free by clicking below at:

Anthera Pharmaceuticals

Hayward, California headquartered Anthera Pharmaceuticals Inc.'s stock declined 2.88%, closing the day at $2.36. A total volume of 10.71 million shares was traded, which was above their three months average volume of 1.12 million shares. The Company's shares have advanced 53.25% in the past month and 14.56% in the previous three months. The stock is trading 48.79% and 45.54% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Anthera Pharma, which focuses on the development and commercialization of medicines for patients with unmet medical needs, have an RSI of 73.31. 

On February 05th, 2018, Anthera Pharma announced that the final patient has completed the last visit in the primary treatment phase of RESULT, a Phase-3 clinical study of Sollpura for exocrine pancreatic insufficiency due to cystic fibrosis. Although the data remains blinded, two successful interim futility analyses were conducted by the independent Data Monitoring Committee, which is comprised of experts appointed by the Cystic Fibrosis Foundation's Therapeutics Development Network.  

On February 21st, 2018, research firm ROTH Capital initiated a 'Buy' rating on the Company's stock, with a target price of $10 per share. Access the free research report on ANTH now by signing up at:

Aralez Pharmaceuticals

On Thursday, shares in Milton, Canada headquartered Aralez Pharmaceuticals Inc. recorded a trading volume of 418,610 shares. The stock ended the day 2.41% higher at $1.70. The Company's shares have advanced 8.97% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 2.13% and 13.05%, respectively. Furthermore, shares of Aralez Pharma, which operates as a specialty pharmaceutical company in Canada, Ireland, and the US, have an RSI of 51.09.

On February 05th, 2018, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, with a target price of $6 per share. Are you already registered with Wall St. Equities? Do so now for free, and get the report on ARLZ at:

Aratana Therapeutics

Leawood, Kansas headquartered Aratana Therapeutics Inc.'s stock dropped 1.22%, finishing yesterday's session at $4.04 with a total trading volume of 269,766 shares. The stock is trading below their 50-day moving average by 18.52%. Shares of the Company, which focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the US and Belgium, have an RSI of 27.02.  

On February 13th, 2018, Aratana Therapeutics announced that it will host a live conference call on March 14th, 2018, at 8:30 a.m. ET to discuss its financial results for Q4 and full year ended December 31st, 2017. Aspiring Member, please take a moment to register below for your free research report on PETX at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Cision View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store